Logo image of 1EVT.MI

EVOTEC SE (1EVT.MI) Stock Fundamental Analysis

Europe - BIT:1EVT - DE0005664809 - Common Stock

6.038 EUR
-0.22 (-3.45%)
Last: 9/29/2025, 7:00:00 PM
Fundamental Rating

2

1EVT gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 20 industry peers in the Life Sciences Tools & Services industry. 1EVT has a bad profitability rating. Also its financial health evaluation is rather negative. 1EVT has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

1EVT had negative earnings in the past year.
1EVT had a positive operating cash flow in the past year.
The reported net income has been mixed in the past 5 years: 1EVT reported negative net income in multiple years.
1EVT had a positive operating cash flow in each of the past 5 years.
1EVT.MI Yearly Net Income VS EBIT VS OCF VS FCF1EVT.MI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M

1.2 Ratios

The Return On Assets of 1EVT (-8.60%) is worse than 85.00% of its industry peers.
The Return On Equity of 1EVT (-18.39%) is worse than 85.00% of its industry peers.
Industry RankSector Rank
ROA -8.6%
ROE -18.39%
ROIC N/A
ROA(3y)-7.25%
ROA(5y)-2.34%
ROE(3y)-14.29%
ROE(5y)-5.27%
ROIC(3y)N/A
ROIC(5y)N/A
1EVT.MI Yearly ROA, ROE, ROIC1EVT.MI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10 -10 -20

1.3 Margins

1EVT has a worse Gross Margin (12.89%) than 85.00% of its industry peers.
In the last couple of years the Gross Margin of 1EVT has declined.
The Profit Margin and Operating Margin are not available for 1EVT so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 12.89%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-16.23%
GM growth 5Y-13.5%
1EVT.MI Yearly Profit, Operating, Gross Margins1EVT.MI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20

More info and screens

3

2. Health

2.1 Basic Checks

1EVT does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, 1EVT has more shares outstanding
Compared to 5 years ago, 1EVT has more shares outstanding
Compared to 1 year ago, 1EVT has an improved debt to assets ratio.
1EVT.MI Yearly Shares Outstanding1EVT.MI Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M
1EVT.MI Yearly Total Debt VS Total Assets1EVT.MI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B 2B

2.2 Solvency

1EVT has an Altman-Z score of 1.17. This is a bad value and indicates that 1EVT is not financially healthy and even has some risk of bankruptcy.
1EVT has a worse Altman-Z score (1.17) than 75.00% of its industry peers.
1EVT has a debt to FCF ratio of 37.11. This is a negative value and a sign of low solvency as 1EVT would need 37.11 years to pay back of all of its debts.
1EVT's Debt to FCF ratio of 37.11 is on the low side compared to the rest of the industry. 1EVT is outperformed by 75.00% of its industry peers.
A Debt/Equity ratio of 0.42 indicates that 1EVT is not too dependend on debt financing.
1EVT has a better Debt to Equity ratio (0.42) than 65.00% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.42
Debt/FCF 37.11
Altman-Z 1.17
ROIC/WACCN/A
WACC7.09%
1EVT.MI Yearly LT Debt VS Equity VS FCF1EVT.MI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500M 1B

2.3 Liquidity

1EVT has a Current Ratio of 1.58. This is a normal value and indicates that 1EVT is financially healthy and should not expect problems in meeting its short term obligations.
1EVT's Current ratio of 1.58 is in line compared to the rest of the industry. 1EVT outperforms 55.00% of its industry peers.
1EVT has a Quick Ratio of 1.49. This is a normal value and indicates that 1EVT is financially healthy and should not expect problems in meeting its short term obligations.
Looking at the Quick ratio, with a value of 1.49, 1EVT belongs to the top of the industry, outperforming 95.00% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 1.58
Quick Ratio 1.49
1EVT.MI Yearly Current Assets VS Current Liabilites1EVT.MI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

More info and screens

3

3. Growth

3.1 Past

The earnings per share for 1EVT have decreased strongly by -136.17% in the last year.
1EVT shows a decrease in Revenue. In the last year, the revenue decreased by -1.41%.
The Revenue has been growing by 12.29% on average over the past years. This is quite good.
EPS 1Y (TTM)-136.17%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%55.56%
Revenue 1Y (TTM)-1.41%
Revenue growth 3Y8.85%
Revenue growth 5Y12.29%
Sales Q2Q%-5.98%

3.2 Future

Based on estimates for the next years, 1EVT will show a very strong growth in Earnings Per Share. The EPS will grow by 20.11% on average per year.
Based on estimates for the next years, 1EVT will show a small growth in Revenue. The Revenue will grow by 7.02% on average per year.
EPS Next Y57.39%
EPS Next 2Y35.45%
EPS Next 3Y27.47%
EPS Next 5Y20.11%
Revenue Next Year-1.21%
Revenue Next 2Y4.03%
Revenue Next 3Y6.51%
Revenue Next 5Y7.02%

3.3 Evolution

The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
1EVT.MI Yearly Revenue VS Estimates1EVT.MI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 200M 400M 600M 800M 1B
1EVT.MI Yearly EPS VS Estimates1EVT.MI Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 0.5 -0.5 1 -1

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

1EVT reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year 1EVT is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
1EVT.MI Price Earnings VS Forward Price Earnings1EVT.MI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20

4.2 Price Multiples

Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of 1EVT indicates a rather expensive valuation: 1EVT more expensive than 85.00% of the companies listed in the same industry.
Based on the Price/Free Cash Flow ratio, 1EVT is valued a bit more expensive than 75.00% of the companies in the same industry.
Industry RankSector Rank
P/FCF 172.19
EV/EBITDA 161.12
1EVT.MI Per share data1EVT.MI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2

4.3 Compensation for Growth

1EVT's earnings are expected to grow with 27.47% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y35.45%
EPS Next 3Y27.47%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for 1EVT!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

EVOTEC SE

BIT:1EVT (9/29/2025, 7:00:00 PM)

6.038

-0.22 (-3.45%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)08-13 2025-08-13/bmo
Earnings (Next)11-05 2025-11-05/bmo
Inst Owners60.42%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap2.14B
Analysts76.67
Price Target9.47 (56.84%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-4.94%
Min Revenue beat(2)-5.1%
Max Revenue beat(2)-4.77%
Revenue beat(4)0
Avg Revenue beat(4)-4.23%
Min Revenue beat(4)-6.12%
Max Revenue beat(4)-0.93%
Revenue beat(8)2
Avg Revenue beat(8)-0.61%
Revenue beat(12)4
Avg Revenue beat(12)1.6%
Revenue beat(16)8
Avg Revenue beat(16)3.56%
PT rev (1m)-2.73%
PT rev (3m)-23.12%
EPS NQ rev (1m)4.76%
EPS NQ rev (3m)-42.86%
EPS NY rev (1m)-63.9%
EPS NY rev (3m)-63.9%
Revenue NQ rev (1m)-0.87%
Revenue NQ rev (3m)-12.9%
Revenue NY rev (1m)-0.72%
Revenue NY rev (3m)-9.79%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 2.76
P/FCF 172.19
P/OCF 19.22
P/B 2.54
P/tB 3.96
EV/EBITDA 161.12
EPS(TTM)-1.11
EYN/A
EPS(NY)-0.18
Fwd EYN/A
FCF(TTM)0.04
FCFY0.58%
OCF(TTM)0.31
OCFY5.2%
SpS2.19
BVpS2.38
TBVpS1.52
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -8.6%
ROE -18.39%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 12.89%
FCFM 1.6%
ROA(3y)-7.25%
ROA(5y)-2.34%
ROE(3y)-14.29%
ROE(5y)-5.27%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-16.23%
GM growth 5Y-13.5%
F-Score4
Asset Turnover0.43
Health
Industry RankSector Rank
Debt/Equity 0.42
Debt/FCF 37.11
Debt/EBITDA 26.48
Cap/Depr 97.54%
Cap/Sales 12.75%
Interest Coverage N/A
Cash Conversion 831.71%
Profit Quality N/A
Current Ratio 1.58
Quick Ratio 1.49
Altman-Z 1.17
F-Score4
WACC7.09%
ROIC/WACCN/A
Cap/Depr(3y)186.39%
Cap/Depr(5y)182.37%
Cap/Sales(3y)22.79%
Cap/Sales(5y)21.48%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-136.17%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%55.56%
EPS Next Y57.39%
EPS Next 2Y35.45%
EPS Next 3Y27.47%
EPS Next 5Y20.11%
Revenue 1Y (TTM)-1.41%
Revenue growth 3Y8.85%
Revenue growth 5Y12.29%
Sales Q2Q%-5.98%
Revenue Next Year-1.21%
Revenue Next 2Y4.03%
Revenue Next 3Y6.51%
Revenue Next 5Y7.02%
EBIT growth 1Y-20.66%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year132.47%
EBIT Next 3Y50.57%
EBIT Next 5Y34.31%
FCF growth 1Y105.04%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y359%
OCF growth 3Y-46.98%
OCF growth 5Y-15.47%